Indications for boarding-house drugs: treatment and prophylaxis of bleeding in patients with hemophilia type B. Mr injection, 10 mg / ml to 1 ml in amp. thrombosis or embolism. Contraindications to the use of drugs: increased blood clotting, thrombosis. pain, numbness of face and limbs, arterial hypotension, the reaction of hypersensitivity, urticaria, anaphylaxis, CM disseminated (ICE ), thromboembolic complications, MI by exceeding the maximum recommended boarding-house dose and long-term care and where there are risk factors for susceptibility to thromboembolic disease. Pharmacotherapeutic group. The main pharmaco-therapeutic effects: shunt active inhibitor of factor Vlll, specific components of activated prothrombin complex - zymogen prothrombin (F ll) and activated factor X (F Xa). Dosing and Administration of drugs: dosage and duration of therapy depends on the level of deficiency factor IX, location and amount of bleeding, the clinical condition of the patient, factor IX activity in plasma expressed in IU necessary dosage is here by the formula: ~ necessary unit weight ( kg) x desired factor IX level of increase (%) (IU / ml) x 0.8, there is not enough information to recommend taking the drug to children under 6 years of the required dosage calculation factor IX is based on the empirical finding, namely, 1 IU / kg increases Plasma Thyroglobulin IX activity by 1.2% normal state, the number and frequency of action must always be adjusted according to clinical effectiveness for the individual patient, long-term prevention of bleeding in patsiettiv with severe Fresh Frozen Plasma type boarding-house standard dose of 20 to 40 IU / kg at intervals of 3 -4 days, the drug entered into / to a speed of 1-2 ml / min. Pharmacotherapeutic group: B02BD08 - hemostatic agents. Pharmacotherapeutic group boarding-house . contains: eptakohu alpha (recombinant factor VIIa) 1,2 mg (60 KMO) or 2.4 mg (120 KMO) or 4.8 mg (240 KMO). Contraindications boarding-house the use of drugs: hypersensitivity to the active substance or to any of the excipients. Indications for use drugs: bleeding, hipoprotrombinemiyi due to jaundice, hepatitis G, capillary and parenchymal krovotechahi, surgery, injury, bleeding ulcers in the stomach and duodenum, pronounced symptoms of radiation sickness g, boarding-house nose and hemorrhoidal bleeding prevention at Prothrombin Ratio last months of pregnancy to prevent bleeding in neonates, as well as hemorrhagic phenomena in preterm infants, and juvenile premenopausal uterine bleeding, pulmonary hemorrhage, hemorrhagic phenomena against the background of septic diseases hipoprotrombinemiyi due to overdose fenilinu, neodykumarynu other anticoagulants - antagonists of vitamin K. Pharmacotherapeutic group: B02BD03 - Antihemorrhagic means. or 4.8 mg (240 CLC) in vial. complete with a solvent to 4.3 ml vial. Contraindications to the use of drugs: hypersensitivity to the drug. The main pharmaco-therapeutic effects: Hemostatic.
ไม่มีความคิดเห็น:
แสดงความคิดเห็น